Validating novel diagnostic assays for tuberculosis in the context of existing tools.

Simple item page
dc.contributor.authorKerkhoff AD
dc.contributor.authorCattamanchi A
dc.contributor.authorMuyoyeta M
dc.contributor.authorDenkinger CM
dc.contributor.authorDowdy DW
dc.date.accessioned2025-09-17T10:26:01Z
dc.date.issued2021-Sep
dc.identifier.doi10.1016/S2214-109X(21)00306-5
dc.identifier.urihttps://pubs.cidrz.org/handle/123456789/11973
dc.identifier.uri.pubmedhttps://pubmed.ncbi.nlm.nih.gov/34416206/
dc.relation.affiliationDivision of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, University of California San Francisco, San Francisco, CA 94110, USA. Electronic address: andrew.kerkhoff@ucsf.edu.
dc.relation.affiliationCenter for Tuberculosis and Division of Pulmonary and Critical Care Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, University of California San Francisco, San Francisco, CA 94110, USA; Uganda Tuberculosis Implementation Research Consortium, Makerere University, Kampala, Uganda.
dc.relation.affiliationCentre for Infectious Disease Research in Zambia (CIDRZ)
dc.relation.affiliationDivision of Tropical Medicine, Center of Infectious Diseases, University of Heidelberg, Heidelberg, Germany.
dc.relation.affiliationUganda Tuberculosis Implementation Research Consortium, Makerere University, Kampala, Uganda; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
dc.sourceThe Lancet. Global health
dc.titleValidating novel diagnostic assays for tuberculosis in the context of existing tools.

Files

Collections

Published